

CAV3 Antibody (monoclonal) (M03)

Mouse monoclonal antibody raised against a partial recombinant CAV3. Catalog # AT1406a

Specification

CAV3 Antibody (monoclonal) (M03) - Product Information

Application WB, E **Primary Accession** P56539 Other Accession NM 001234 Reactivity Human Host mouse Clonality **Monoclonal** Isotype IgG2b Kappa 17259

Calculated MW

CAV3 Antibody (monoclonal) (M03) - Additional Information

Gene ID 859

Other Names

Caveolin-3, M-caveolin, CAV3

Target/Specificity

CAV3 (NP 001225, 1 a.a. ~ 83 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Dilution

WB~~1:500~1000

E~~N/A

Format

Clear, colorless solution in phosphate buffered saline, pH 7.2.

Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

Precautions

CAV3 Antibody (monoclonal) (M03) is for research use only and not for use in diagnostic or therapeutic procedures.

CAV3 Antibody (monoclonal) (M03) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot




- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

CAV3 Antibody (monoclonal) (M03) - Images



Antibody Reactive Against Recombinant Protein. Western Blot detection against Immunogen (34.87 KDa).




Detection limit for recombinant GST tagged CAV3 is approximately 1ng/ml as a capture antibody.


CAV3 Antibody (monoclonal) (M03) - Background

This gene encodes a caveolin family member, which functions as a component of the caveolae plasma membranes found in most cell types. Caveolin proteins are proposed to be scaffolding proteins for organizing and concentrating certain caveolin-interacting molecules. Mutations identified in this gene lead to interference with protein oligomerization or intra-cellular routing, disrupting caveolae formation and resulting in Limb-Girdle muscular dystrophy type-1C (LGMD-1C), hyperCKemia or rippling muscle disease (RMD). Alternative splicing has been identified for this locus, with inclusion or exclusion of a differentially spliced intron. In addition, transcripts utilize multiple polyA sites and contain two potential translation initiation sites.

CAV3 Antibody (monoclonal) (M03) - References

Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086.Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. Roberts KE, et al. Gastroenterology, 2010 Jul. PMID 20346360.Bedside diagnosis of rippling muscle disease in CAV3 p.A46T mutation carriers. Sundblom J, et al. Muscle Nerve, 2010 Jun. PMID 20229577.Human variation in alcohol response is







influenced by variation in neuronal signaling genes. Joslyn G, et al. Alcohol Clin Exp Res, 2010 May. PMID 20201926. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Talmud PJ, et al. Am J Hum Genet, 2009 Nov. PMID 19913121.